🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

CBCT Guided Markerless SBRT for Renal Cell Cancer

RecruitingNAAges 18 Years - anyAllErasmus Medical Center
NCT07402109 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to improve the treatment of kidney tumors using radiotherapy, by investigating whether kidney cancer can be more effectively irradiated with the help of new imaging techniques

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients with histologically proven non-metastastic RCC or high suspicion of RCC based on imaging without histological evidence * No metastatic lesions * Patients must be 18 years or older * Ability to understand the requirements of the study and to give written informed consent, as determined by the treating physician. Written informed consent Exclusion Criteria: * Previous high-dose radiotherapy in the region of the kidney
💊

What it tests

  • Additional radiation due to imaging
📍

Where

1 site
Erasmus MC
Rotterdam, Netherlands
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy